[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$rhhby Graphic](https://lunarcrush.com/gi/w:26/t:$rhhby.png) $rhhby

Roche's engagements and mentions are surging due to positive clinical data and strategic investments. FDA may fast-track drug reviews for companies aligning prices with international rates.

### About $rhhby
Financial analysis of Roche (RHHBY), focusing on market sentiment, clinical trial results, and regulatory approvals.  

### Insights [#](/topic/$rhhby/insights)
- $rhhby creators is up XXXXX% from the previous week.
- $rhhby engagements is up XXXXX% from the previous week.
- $rhhby mentions is up XX% from the previous week.
- $rhhby posts created is up XXXXXX% from the previous week.

### Engagements: XXXXXX [#](/topic/$rhhby/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$rhhby/c:line/m:interactions.svg)  
[Engagements 24-Hour Chart Data](/topic/$rhhby/time-series/interactions.tsv)  
**Current Value**: XXXXXX  
**Daily Average**: XXXXXX  
**1 Week**: XXXXXXX +47%  
**1 Month**: XXXXXXX -XX%  
**6 Months**: XXXXXXXXX -XX%  
**1 Year**: XXXXXXXXX +25%  
**1-Year High**: XXXXXXX on 2024-12-05  
**1-Year Low**: XXX on 2025-01-26  

| Social Network | X      | Reddit |
| -------------- | -      | ------ |
| Engagements    | XXXXXX | X      |
  

  
  
### Mentions: XXX [#](/topic/$rhhby/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$rhhby/c:line/m:posts_active.svg)  
[Mentions 24-Hour Chart Data](/topic/$rhhby/time-series/posts_active.tsv)  
**Current Value**: XXX  
**Daily Average**: XX  
**1 Week**: XXX +90%  
**1 Month**: XXX +55%  
**6 Months**: XXXXX +3.30%  
**1 Year**: XXXXX +89%  
**1-Year High**: XXX on 2024-11-17  
**1-Year Low**: XX on 2025-01-27  

| Social Network | X   | Reddit |
| -------------- | -   | ------ |
| Mentions       | XXX | X      |
  

  
  
### Creators: XX [#](/topic/$rhhby/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$rhhby/c:line/m:contributors_active.svg)  
[Creators 24-Hour Chart Data](/topic/$rhhby/time-series/contributors_active.tsv)  
XX unique social accounts have posts mentioning $rhhby in the last XX hours which is down XXXX% from XX in the previous XX hours
**Daily Average**: XX  
**1 Week**: XX +13%  
**1 Month**: XXX -XX%  
**6 Months**: XXX +5.10%  
**1 Year**: XXXXX +158%  
**1-Year High**: XXX on 2024-12-03  
**1-Year Low**: XX on 2025-01-27  

The most influential creators that mention $rhhby in the last XX hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) | X    | XXXXX     | XX    | XXXXX       |
| [@BiopharmIQ](/creator/twitter/BiopharmIQ)           | X    | XXXXXX    | X     | XXXXX       |

[View More](/list/creators/$rhhby/100)
  
  
### Sentiment: XX% [#](/topic/$rhhby/sentiment)
---
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$rhhby/c:line/m:sentiment.svg)  
[Sentiment 24-Hour Chart Data](/topic/$rhhby/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XX% -XX%  
**1 Month**: XX% -XX%  
**6 Months**: XX% -XX%  
**1 Year**: XX% -XX%  
**1-Year High**: XXX% on 2024-10-18  
**1-Year Low**: XX% on 2024-12-22  

**Most Supportive Themes**
- **Positive Clinical Data and Regulatory Approvals:** (47%) Positive clinical trial results and regulatory approvals are generating positive sentiment.
- **Strategic Investments and Collaborations:** (24%) Roche's strategic investments and collaborations signal growth and innovation.
- **Dividend Aristocrat Status:** (9%) Roche's financial stability is highlighted by its inclusion in lists of international dividend aristocrats.
  
**Most Critical Themes**
- **Columvi Expansion Faces US Regulatory Hurdles:** (2.2%)  Potential regulatory hurdles for Columvi expansion in the US may impact financial performance.
- **Drug Pricing Pressures:** (1.8%)  The reimplementation of the drug pricing order may impact large-cap drugmakers.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %   |
| ------- | -------- | -   | ------- | -   | -------- | -   |
| X       | XXXXX    | XX% | XXXXX   | XX% | XXXXX    | XX% |
| Reddit  | X        | X%  | X       | X%  | X        | X%  |
|         |          |     |         |     |          |     |
| Total   | XXXXX    | XX% | XXXXX   | XX% | XXXXX    | XX% |
  


**Top assets mentioned**
In the posts about $rhhby in the last XX hours

[Hims & Hers Health, Inc. (HIMS)](/topic/$hims)
[Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn)
[GSK plc (GSK)](/topic/$gsk)
[Eli Lilly and Company (LLY)](/topic/$lly)
[Novartis AG (NVS)](/topic/$nvs)
[Bitcoin Incognito (XBI)](/topic/$xbi)
[Gilead Sciences, Inc. (GILD)](/topic/$gild)
[Biogen Inc (BIIB)](/topic/$biib)
[Synthetify (SNY)](/topic/$sny)
[Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt)

**Top topics mentioned**
In the posts about $rhhby in the last XX hours

[manat](/topic/manat), [$hims](/topic/$hims), [$vani](/topic/$vani), [hims](/topic/hims), [pfe](/topic/pfe), [$zldpf](/topic/$zldpf), [jnj](/topic/jnj), [abbv](/topic/abbv), [$regn](/topic/$regn), [$gsk](/topic/$gsk), [$lly](/topic/$lly), [stocks](/topic/stocks), [$nvs](/topic/$nvs), [$xbi](/topic/$xbi), [$gild](/topic/$gild), [$asnd](/topic/$asnd), [$repl](/topic/$repl), [$biib](/topic/$biib), [$sny](/topic/$sny), [$srpt](/topic/$srpt), [$kalv](/topic/$kalv), [bloomberg](/topic/bloomberg), [tak](/topic/tak), [$tak](/topic/$tak), [rog](/topic/rog), [stockmarket](/topic/stockmarket), [investment](/topic/investment), [gibraltar pound](/topic/gibraltar-pound), [$sgmo](/topic/$sgmo), [nvda](/topic/nvda), [stocks healthcare](/topic/stocks-healthcare), [china](/topic/china), [soundcloud](/topic/soundcloud), [$jnj](/topic/$jnj), [teva](/topic/teva), [$33m](/topic/$33m), [$aard](/topic/$aard), [tariffs](/topic/tariffs), [donald trump](/topic/donald-trump), [eli](/topic/eli), [acquisition](/topic/acquisition), [$zts](/topic/$zts), [new era](/topic/new-era), [insider](/topic/insider), [$8b](/topic/$8b), [$vtrs](/topic/$vtrs), [Sentiment](/topic/sentiment), [sarepta therapeutics inc](/topic/sarepta-therapeutics-inc), [$djt](/topic/$djt), [$him](/topic/$him), [$ipsc](/topic/$ipsc), [$vrna](/topic/$vrna), [$rcus](/topic/$rcus), [$mreo](/topic/$mreo), [nasdaq](/topic/nasdaq), [sarepta therapeutics](/topic/sarepta-therapeutics), [goog](/topic/goog), [$vrtx](/topic/$vrtx), [otc](/topic/otc), [$rare](/topic/$rare), [$vwagy](/topic/$vwagy), [$srzn](/topic/$srzn), [$eypt](/topic/$eypt), [$cogt](/topic/$cogt), [$gald](/topic/$gald), [$rogsw](/topic/$rogsw), [$tptx](/topic/$tptx), [$gbt](/topic/$gbt), [$bgne](/topic/$bgne), [jacob](/topic/jacob), [$slno](/topic/$slno), [1b](/topic/1b), [$900m](/topic/$900m), [$1b](/topic/$1b), [$9b](/topic/$9b), [coins ai](/topic/coins-ai), [$edit](/topic/$edit), [mental health](/topic/mental-health), [coins healthcare](/topic/coins-healthcare), [$pph](/topic/$pph), [$xph](/topic/$xph), [$ibb](/topic/$ibb), [msi](/topic/msi), [$vlgea](/topic/$vlgea), [$vcisy](/topic/$vcisy), [$uvv](/topic/$uvv), [$uovey](/topic/$uovey), [mounjaro](/topic/mounjaro), [wegovy](/topic/wegovy), [ozempic](/topic/ozempic), [drugs](/topic/drugs), [investin](/topic/investin), [bmi](/topic/bmi), [$uti](/topic/$uti), [told](/topic/told), [dividend](/topic/dividend), [$srptfda](/topic/$srptfda), [approved](/topic/approved), [$rhhbf](/topic/$rhhbf), [$blk](/topic/$blk)

### Top Social Posts [#](/topic/$rhhby/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"Sarepta's Elevidys Is a Bigger Scam Than the Trump or Melania Coin @POTUS @realDonaldTrump @PressSec @RobertKennedyJr @MartyMakary $SRPT $BTC $MSTR $AZN $DJT $PFE $RHHBY $IEP $JPM $BAC"  
[@brianfires](/creator/x/brianfires) on [X](/post/tweet/1946643609677164553) 2025-07-19 18:49:38 UTC XXX followers, XXX engagements


"🦉 For weight loss CagriSema ranked highest with XXXXX kg followed by tirzepatide and retatrutide. Adverse events rose with dose notably GI issues making tolerability a key factor. $NVO $LLY $AZN $SNY $GSK $PFE $RHHBY $ZLDPF $VKTX $VANI $HIMS #glp1 #diabetes"  
[@AponiaAnalytics](/creator/x/AponiaAnalytics) on [X](/post/tweet/1946592287380632026) 2025-07-19 15:25:41 UTC 4965 followers, XXX engagements


"🦉 Tirzepatide led glycaemic control with a XXXX% HbA1c drop and XXXX mmol/L fasting glucose outperforming XX other GLP-1RAs. Its dose-efficacy was linear peaking at XX mg weekly. $NVO $LLY $AZN $SNY $GSK $PFE $RHHBY $ZLDPF $VKTX $VANI $HIMS #glp1 #diabetes"  
[@AponiaAnalytics](/creator/x/AponiaAnalytics) on [X](/post/tweet/1946592284067192895) 2025-07-19 15:25:41 UTC 4965 followers, XXX engagements


"💼Comparative effectiveness of GLP-1 receptor agonists on glycaemic control body weight and lipid profile for type X diabetes $NVO $LLY $AZN $SNY $GSK $PFE $RHHBY $ZLDPF $VKTX $VANI $HIMS #glp1 #diabetes"  
[@AponiaAnalytics](/creator/x/AponiaAnalytics) on [X](/post/tweet/1946592280942375206) 2025-07-19 15:25:40 UTC 4965 followers, XXX engagements